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A b s t r a c t  A variant of the angiotensinogen gene, M235T, 
has been associated with essential hypertension in se- 
lected subjects from Paris, France and Salt Lake City, 
Utah. In the present report, we studied a population-based 
sample consisting of  104 subjects diagnosed with hyper- 
tension before age 60 and 195 matched nonnotensive in- 
dividuals from Rochester, Minnesota. We determined 
whether there was a relationship between the M235T 
polymorphism of the angiotensinogen gene and the occur- 
rence of essential hypertension using two methods. First, 
a contingency chi-square analysis was carried out to test 
for an association between the M235T polymorphism and 
hypertension status. Second, multivariable conditional lo- 
gistic regression was used to determine whether variation 
at the M235T polymorphism was a significant predictor 
of the probability of having essential hypertension. We 
detected no statistically significant association between 
the M235T polymorphism and the occurrence of essential 
hypertension. In particular, the association was not signif- 
icant in either gender or in a subset of  severely hyperten- 
sive subjects requiring two or more anti-hypertensive 
medications. Furthermore, variation in the number of 
M235T alleles did not make a significant contribution to 
predicting the probability of having essential hyperten- 
sion, either alone or in conjunction with other predictor 
variables. These results suggest that the contribution of  
variation in the angiotensinogen gene to the occurrence of  
essential hypertension is less than initially suspected, or 
may not be constant across populations. 
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Introduction 
In westernized societies, essential hypertension affects 
more than 20% of the adult population and contributes to 
cardiovascular complications that are a major cause of 
morbidity and mortality in the general population. Bio- 
metric studies have provided strong evidence for a genetic 
component to the determination of interindividual blood 
pressure variation (Ward 1990). Although the genetic loci 
involved have not been identified, genes encoding the 
components of the renin-angiotensin system (RAS) are 
among the candidates, and polymorphic variations affect- 
ing the function or expression of these genes may consti- 
tute the basis for a genetic predisposition to essential hy- 
pertension. Stimulation of the RAS leads to the produc- 
tion of angiotensin II (Ang II), which raises blood pres- 
sure by causing vasoconstriction, aldosterone secretion, 
and increased sodium and water reabsorption by the kid- 
neys. Ang II is produced by a series of chemical reactions, 
which includes the cleavage of angiotensinogen to an- 
giotensin I by renin, followed by the cleavage of an- 
giotensin I to angiotensin II by the angiotensin-converting 
enzyme (ACE). Epidemiologic and biochemical data sup- 
port a direct relationship between plasma angiotensinogen 
and blood pressure levels (Fasola et al. 1968; Mrnard et 
al. 1991; Watt et al. 1992; Kimura et al. 1992). 
Jeunemaitre et al. (1992) have investigated the role of 
the gene coding for angiotensinogen in essential hyperten- 
sion and have demonstrated linkage between a marker in 
this gene and an unidentified locus influencing the occur- 
rence of  essential hypertension. This result was recently 
confirmed by Caulfield et al. (1994) in 63 white European 
families. Jeunemaitre et al. (1992) have also shown that a 
T7~ substitution in exon 2 of  the gene, encoding a 
Met235----)Thr variant, referred to as M235T, is associated 
with elevated plasma angiotensinogen levels and essential 
hypertension in subjects from Paris, France and Salt Lake 
City, Utah. These results, directly implicating variation in 
the angiotensinogen gene in determining variation in 
plasma angiotensinogen and blood pressure levels, were 
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in agreement with previous epidemiological data demon- 
strating higher plasma angiotensinogen concentrations in 
hypertensive subjects and their off'spring as compared to 
normotensive individuals (Fasola et al. 1968). However, 
the hypertensive patients studied by Jeunemaitre et al. 
(1992) were not representative of the general hypertensive 
population, and thus do not provide information about the 
impact of the M235T polymorphism on the occurrence of 
essential hypertension in the population-at-large. There- 
fore, we have examined the M235T variant of the an- 
giotensinogen gene in a population-based sample of early- 
onset hypertensive subjects and their matched normoten- 
sive controls from Rochester, Minnesota. 
Materials and methods 
motensive subjects. Genotype frequencies did not differ from 
Hardy-Weinberg expectation in both groups (data not shown). Sta- 
tistical comparison of allele frequencies of the M235T polymor- 
phism between hypertensive and normotensive individuals was 
carried out using two methods. First, a contingency Z 2 analysis 
with one degree of freedom was used to test for an association be- 
tween the relative frequencies of the M235T variant allele and hy- 
pertension status. Second, conditional logistic regression on the 
matched data set (Breslow and Day 1980; Hosmer and Lemeshow 
1989) was used to determine whether allelic variation at the 
M235T locus was a significant predictor of the probability of hav- 
ing hypertension. Conditional logistic regression is a modification 
of the usual logistic regression method taking into account the 
matching of normotensive subjects to hypertensive subjects. The 
number of susceptibility alleles as defined by Jeunemaitre et al. 
(1992) was used as the predictor variable with three possible out- 
comes - 0, l, and 2. Comparable results were obtained from a par- 
allel analysis using two indicator variables to encode the three 
genotype categories (results not shown). 
All of the individuals in this study were previous participants in 
the Rochester Family Heart study (RFHS), a population-based 
study initiated in 1984 to investigate the role of genetic factors in 
the occurrence of hypertension and cardiovascular disease in 
Rochester, Minn. Individuals participating in the RFHS are mem- 
bers of multigeneration pedigrees ascertained through households 
having two or more children in the schools of Rochester, Minn.; 
these pedigrees were selected without regard to health status of the 
family members. All individuals provided their informed consent 
to participate in the RFHS. Recruitment and examination protocols 
of participants in the RFHS have been described in detail by 
Turner et al. ( 1985, 1989) and Turner and Michels (1991 ). 
Of the 3938 individuals who participated in the RFHS between 
1984 and 1993, we selected 104 individuals who had been diagnosed 
with hypertension before age 60 and had a body mass index (BM1) 
of less than 32 kg/m 2. Subjects were defined as having essential hy- 
pertension if (1) they reported previous diagnosis of hypertension 
and were receiving anti-hypertensive treatment at the time of exam- 
ination or (2) had a systolic blood pressure greater than 140 mm Hg 
or a diastolic blood pressure greater than 90 mm Hg at the time of 
examination and (3) had no evidence of causes of secondary hyper- 
tension. In this sample, 95% of hypertensive women and 87c~ of hy- 
pertensive men had been previously diagnosed and were taking 
blood-pressure-lowering medication at the time of examination. 
To test for an association between the M235T polymorphism in 
the angiotensinogen gene and the occurrence of essential hyper- 
tension, we also selected 195 normotensive individuals. Up to two 
normotensive controls were matched to each hypertensive subject 
for gender, age (+ 1 year), and BMI (+ 2 kg/m2). The normotensive 
subjects had a systolic blood pressure less than 140 mm Hg and a 
diastolic blood pressure less than 90 mm Hg at the time of partici- 
pation in the RFHS, had no previous diagnosis of hypertension, 
and were never treated with anti-hypertensive medication. All hy- 
pertensive and nonnotensive subjects were unrelated Caucasians. 
We have typed the M235T variant of angiotensinogen using 
single-strand conformation analysis (Orita et al. 1989) following 
the polymerase chain reaction (PCR) amplification of the appro- 
priate region of the angiotensinogen gene. The M235T genotypes 
were readily distinguishable on the autoradiogram. Direct DNA 
sequencing of two amplification products (one of each homozy- 
gous genotype) was performed to verify that the variation detected 
by this method was at the expected nucleotide position (data not 
shown) as reported by Jeunemaitre et al. (1992). 
To describe the distribution of quantitative variables in the 
groups of hypertensive and normotensive subjects, gender-specific 
means and standard deviations were computed. Within each gen- 
der, Student's t-test was used to evaluate differences in means be- 
tween the hypertensive and normotensive groups. Satterthwaite's 
approximation to the t-test was used when the variances differed 
significantly between diagnostic groups. 
Genotypes were scored for each individual, and allele frequen- 
cies were estimated by gene counting in hypertensive and nor- 
Results 
Characteristics of the hypertensive subjects and their 
matched normotensive controls are described by gender in 
Table 1 Characteristics of the samples matched for gender, age, and 
body mass index of hypertensive and normotensive subjects from 
Rochester, Minnesota by gender. Values given are averages _+ one 
standard deviation (BP Blood pressure, Rx medication, Na/Li CNT 




Sample size (n) 59 111 
Age (years) 64 + 10 63 + 9 
Age at diagnosis (years) 50 + 6 - 
Body Mass Index (kg/m 2) 25.6 + 2.6 25.5 + 2.5 
Systolic BP (ram Hg) 144.5 _+ 29.5 120.5 + 11.6", ** 
Diastolic BP (ram Hg) 77.8 + 10.3 67.4 + 7.4*, ** 
Antihypertensive Rx (Y/N) 56/3 
Hormone use ~' (Y/N) 8/51 12/99 
Total cholesterol (mg/dl) 224.3 + 44.4 212.9 +_ 36.9 
Triglycerides (mg/dl) 137,9 + 57,2 123.3 _+ 49.9 
Na/Li CNT (~lmol/1 RBC/h) 325.4 + 87,8 258.1 + 95.9* 
apo CII (mg/dl) 2.9 + 1.0 2.6 + 0.8 
Men 
Sample size (n) 45 84 
Age (years) 60 +_ 10 61 + 10 
Age at diagnosis (years) 48 + 7 - 
Body Mass Index (kg/m 2) 26.5 + 2.5 26.6 + 2.5 
Systolic BP (mm Hg) 137.5+ 1 9 . 4  116.5_+ 11.3",** 
Diastolic BP (mm Hg) 82.0 _+ 9.0 70.9 _+ 8.2*, ** 
Antihypertensive Rx (Y/N) 39/6 
Total cholesterol (mg/dl) 200.8 _+ 36.9 200.6 _+ 38.9 
Triglycerides (mg/dl) 158.2 _+ 65.1 132.1 +_ 64.1" 
Na/Li CNT (Bmol/l RBC/h) 367.2 _+ 155.1 301.1 + 120.8",** 
apo CII (mg/dl) 2.9 _+ 1.0 2.4 + 0.8* 
* Statistically significant difference in means (P < 0.05) between hy- 
pertensive and normotensive subjects: ** statistically significant dif- 
ference in variances (P < 0.05) between hypertensive and normoten- 
sive subjects 
~'Estrogen or estrogen plus progesterone 
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Table 1. The group of  104 hypertensive subjects included 
45 men and 59 women.  The group of  195 normotensive 
subjects included 84 men and 111 women.  Because of  
matching,  the ratio o f  men to women  did not differ signif- 
icantly between diagnostic groups, and the distributions 
of  age and BMI in normotensive subjects were not signif- 
icantly different f rom those in hypertensive subjects o f  the 
same gender. The mean age at diagnosis o f  essential hy- 
pertension was 50 years for women and 48 years for men. 
Within each gender, average systolic and diastolic blood 
pressures were significantly higher in hypertensive sub- 
jects than in normotensive subjects (144 and 78 m m  Hg, 
respectively, for hypertensive women  vs 120 and 67 m m  
Hg, respectively, for normotensive women;  137 and 82 
m m  Hg, respectively, for hypertensive men vs 116 and 71 
m m  Hg, respectively, for normotensive men). 
Since the prevalence o f  essential hypertension differs 
between men and women  (Kaplan 1994), and an- 
giotensinogen is known to be under the control of  estro- 
gens (Cain et al. 1971), we investigated the potential as- 
sociation between the M235T polymorphism and essen- 
tial hypertension in each gender separately (Table 2). In 
women,  there was no significant difference in allele fre- 
quencies between hypertensive and normotensive subjects 
(0.38 vs 0.36; P = 0.70). When  women  taking hormones 
were excluded from the analysis, the difference in allele 
frequencies between hypertensive and normotensive fe- 
male subjects was larger (0.40 vs 0.34), but did not reach 
statistical significance (P = 0.28). Likewise, in men, there 
Table 2 Allele frequencies of the angiotensinogen M235T variant 
in Rochester, Minnesota (n sample size; qM235T allele frequency of 
the M235T variant, P probability of observing allele frequency dif- 
ferences by chance) 
n qM235T P* 
Women 
Hypertensive 59 0.38 
Normotensive 111 0.36 
More severe hypertensive a 22 0.45 
Normotensive 41 0.35 
Excluding women taking hormones 
Hypertensive 51 0.40 
Normotensive 99 0.34 
More severe hypertensive 19 0.47 
Normotensive 38 0.35 
Men 
Hypertensive 45 0.44 
Normotensive 84 0.47 
More severe hypertensive 23 0.47 
Normotensive 44 0.49 
Genders combined 
Hypertensives 104 0.41 
Normotensives 195 0.40 
More severe hypertensives 45 0.47 
Normotensives 85 0.42 
aHypertensive individuals taking two or more anti-hypertensive 
medications 
was no significant difference in allele frequencies be- 
tween hypertensives and matched normotensive controls 
(0.44 vs 0.47; P = 0.69). 
We next determined whether allelic variation at the 
M235T locus predicts the probability o f  having essential 
hypertension using conditional logistic regression on 
these matched data. The number  o f  variant M235T alleles 
was introduced as the predictor variable in the conditional 
logistic regression model with three possible outcomes - 
0, 1, or 2. Results f rom the conditional regression analysis 
on matched samples stratified by gender are summarized 
in Table 3. The number  o f  variant alleles was not a signif- 
icant predictor of  the probability o f  having hypertension 
in either gender (P = 0.78 in women;  P = 0.59 in men). 
The probability o f  having hypertension is modif ied by 
a large number  of  factors. Therefore, we asked whether 
variation in the number  of  M235T alleles was a signifi- 
cant predictor o f  an individual 's probability of  having hy- 
pertension while simultaneously considering the effects of  
other risk factor variables. Two separate prediction equa- 
tions were considered. In the first equation, the significant 
Table 3 Results of the conditional logistic regression analyses 
predicting the probability of having hypertension in Rochester, 
Minnesota (P probability of detecting a significant effect of the 
number of M235T alleles by chance, C.I. confidence interval) 
Predictor variable Parameter P Odds ratio b 
estimate a [95% C.I.] 
M235T alleles only 
Women 
Men 
M235T alleles with 
significant predictors 
of essential hypertension 




0.27 M235T alleles with 
significant predictors of 
essential hypertension 
0.28 identified in 
Turner et al. (1992) d 
0.22 Women 
Men 
0.065 0.78 1.068 
[0.670-1.702] 
-0.143 0.59 0.866 
[0.512-1.465] 
~9.004 0.99 0.996 
[0.565-1.757] 
0.017 0.95 1.017 
[0.562-1.841] 
~).033 0.91 1.034 
[0.568-1.880] 
~3.017 0.96 0.983 
[0.531-1.819] 
0.69 
a Change in the logarithm of the odds of having essential hyperten- 
sion per unit increase in the number of M235T alleles 
0.90 bChange in the odds of having essential hypertension per unit in- 
crease in the number of M235T alleles 
c Significant predictors of essential hypertension identified by step- 
wise conditional logistic regression in this sample were sodium- 
0.98 lithium countertransport, sodium-lithium countertransport-squared 
(in women), and apolipoprotein CII levels (in men) 
0.50 dSignificant predictors of essential hypertension in Turner et al. 
(1992) were age, BMI, sodium-lithium countertransport levels, 
apolipoprotein CII levels, apolipoprotein CII levels squared, and 
apo AI levels (in women only) 
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predictor variables were identified in this sample by for- 
ward stepwise conditional logistic regression, both first- 
and second-order terms were allowed to enter the model. 
Information about the significant predictor variables was 
fixed in the model and then the information about the 
M235T allele was added to the model to test the null hy- 
pothesis that this allele did not significantly predict the 
probability of having essential hypertension. In the second 
equation, the significant predictor variables of essential hy- 
pertension in the RFHS identified by Turner et al. (1992) 
were first included, and then information about the number 
of M235T alleles a person carries was added to the model. 
The results of these analyses are summarized in Table 3. 
For women, the significant predictors of the probability of 
having hypertension were sodium/lithium countertranport 
level and sodium/lithium countertransport level-squared. 
For men, they were sodium/lithium countertransport and 
apolipoprotein CII levels. In neither gender did variation in 
the number of M235T alleles significantly predict variation 
in the probability of having hypertension after the effects of 
these predictors had been considered (P = 0.99, in women; 
P = 0.95, in men). Significant predictors of essential hy- 
pertension in women taking part in the RFHS as previously 
identified by Turner et al. (1992) were age, BMI, 
sodium/lithium countertransport level, plasma apolipopro- 
rein CII level, apolipoprotein CII level-squared, and 
apolipoprotein AI level. For men, the predictors were the 
same as for women, except apolipoprotein AI level was not 
a significant predictor. Likewise, variation in the number of 
M235T alleles did not significantly predict variation in the 
probability of having hypertension in either gender after 
the effects of these risk factors had been considered (P = 
0.91 in women; P = 0.96 in men). 
The effect of the genetic variation at the M235T locus 
of the angiotensinogen gene may not be simply additive to 
the effects of variation in other predictors. Therefore, we 
asked whether the relationship between the probability of 
having hypertension and its predictors is influenced by the 
M235T polymorphism of the angiotensinogen gene. 
Within each gender, terms representing interactions be- 
tween the number of M235T variant alleles and each pre- 
dictor previously identified by stepwise conditional logistic 
regression (first-order terms only) were successively added 
to the model. Interactions between the number of M235T 
alleles and age or BM! were also considered. In neither 
gender was the relationship between the probability of hav- 
ing hypertension and its predictors modified by variation in 
the number of M235T alleles (result not shown). 
A previous study reported an elevation of the frequency 
of the M235T allele in subsets of severely affected hyper- 
tensives as defined by the requirement for two or more 
blood pressure lowering medications (Jeunemaitre et al. 
1992). In our sample, there were 45 individuals, 22 women 
and 23 men, with severe hypertension by this definition. 
There was no significant association in either gender be- 
tween the M235T polymorphism and severe essential hy- 
pertension (P = 0.27 in women; P = 0.90 in men). How- 
ever, because of the small number of severe hypertensive 
individuals in each gender, we next tested for an associa- 
tion of this polymorphism with severe essential hyperten- 
sion for women and men combined. The estimated fre- 
quency of the M235T allele for each gender combined in 
this subset is shown in Table 2. The frequency of the vari- 
ant allele was elevated in severe hypertensives relative to 
the overall sample of hypertensives (0.47 vs 0.41). Al- 
though the difference in M235T allele frequency between 
the severe hypertensives and their matched normotensive 
controls (0.47 vs 0.42) was greater than that between hy- 
pertensives and normotensives in the total sample (0.41 vs 
0.40), it did not reach statistical significance (P = 0.50). 
Table 4 summarizes the allele frequencies at the 
M235T locus obtained in three previous studies. The fre- 
quency of the M235T variant in the sample of normoten- 
sive controls from Rochester was not significantly differ- 
ent from those reported in other Caucasian normotensive 
populations (0.38 in Paris, France, 0.35 in Salt Lake City, 
Table 4 Comparison of allele 
frequencies of the M 2 3 5 T  Population n qM235r P 
polymorphism in several Cau- 
casian populations (qM235T al- 
lele frequency of the M235T 
variant of the angiotensinogen 
gene, W/M Women/Men, NR 
not reported, P probability of 
observing an allele frequency 
difference between hyperten- 
sive and normotensive subjects 
by chance) 
For combined samples from 
Salt Lake City and Paris 
b Data reported in Jeunemaitre 
et al. (1992) 
Data reported in Jeunemaitre 
et al. (1993) 
dData reported in Bennett et al. 
(1993) 
Rochester, Minn. 
Hypertensive (W/M) 104 (59/45) 0.41 (0.38/0.44) 0.98 
Normotensive (W/M) 195 (111/99) 0.40 (0.36/0.47) 
Salt Lake City, Utah 
Hypertensive (W/M) ~' 264 (206/224) 0.44 (0.51/0.44) ~' < 0.05 
Normotensive (W/M) ~' 280 (NR) 0.35 (0.37/NR) a 
Paris, France b 
Hypertensive (W/M)" 166 (206/224) 0.52 (0.51/0.44) a < 0.001 
Normotensive (W/M) ~ 184 (NR) 0.38 (0.37/NRp 
Paris, France c 
Hypertensive (mild) 136 0.44 0.25 < P < 0.50 
Hypertensive (severe) 119 0.49 < 0.05 
Normotensive 90 0.38 
Sydney, Australia d 
Hypertensive (W/M) 92 (44/48) 0.42 (0.43/0.42) 0.63 
Normotensive (W/M) 95 (55/40) 0.39 (0.37/0.41) 
Utah, 0.39 in Sydney, Australia, and 0.40 in Rochester). 
In contrast, the frequency of this allele was 0.71 in a sam- 
ple of 80 Japanese normotensive females and 0.73 in a 
sample of 42 Hispanics from Utah (Ward et al. 1993). 
Therefore, it appears that the allele frequency variability 
at the M235T locus is small among Caucasian populations 
relative to that observed among other racial groups. In the 
hypertensive group, the M235T allele frequency in the 
sample of hypertensive males of Rochester was also com- 
parable to that in other studies (0.44 in Rochester; 0.44 in 
Paris, and Salt Lake City, combined; 0.42 in Sydney), but 
greater variability in allele frequencies was observed 
among the hypertensive females in the three studies (0.51 
in hypertensive females from Paris and Salt Lake City, 
combined; 0.43 in hypertensive females from Sydney; 
0.38 in hypertensive females from Rochester). 
Discussion 
Several lines of evidence suggest that angiotensinogen 
gene variation may have a role in predisposing individuals 
to essential hypertension. First, angiotensinogen is a pre- 
cursor of angiotensin II, a peptide with powerful vasocon- 
strictor and antinatriuretic effects. Second, there is a sig- 
nificant correlation between plasma angiotensinogen lev- 
els and diastolic blood pressure (Walker et al. 1979), and 
hypertensive subjects and their offspring have higher av- 
erage plasma angiotensinogen levels than normotensives 
(Fasola et al. 1968). Third, blood pressure was shown to 
increase or decrease after injection of angiotensinogen or 
antibodies to angiotensinogen, respectively (Mrnard et al. 
1991; Gardes et al. 1989). Fourth, transgenic animal mod- 
els overexpressing the angiotensinogen gene have higher 
blood pressure levels than controls (Kimura et al. 1992). 
Finally, two independent studies (Jeunemaitre et al. 1992; 
Caulfield et al. 1994) have reported linkage between the 
angiotensinogen gene and essential hypertension in se- 
lected hypertensive subjects from Paris, France, Salt Lake 
City, Utah, and southeast England. 
We have studied a population-based sample of 104 
subjects with onset of hypertension at less than 60 years 
and 195 matched normotensive individuals from Ro- 
chester, Minn. We used both a contingency E2 analysis 
and a multivariable conditional logistic regression analy- 
sis for matched data to determine whether there was a re- 
lationship between a polymorphism in the angiotensino- 
gen gene, M235T, and the occurrence of essential hyper- 
tension in this cross-sectional study. We found no associ- 
ation between the M235T polymorphism of the an- 
giotensinogen gene and hypertension, and we showed that 
variation in the number of M235T alleles did not signifi- 
cantly predict variation in the probability of having hyper- 
tension in either men or women. We also showed that the 
relationship between the probability of having hyperten- 
sion and its predictors was not modified by the number of 
variant alleles at the M235T locus of the angiotensinogen 
gene. In addition, this polymorphism was not significantly 
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associated with severe hypertension, as defined by the 
need for multiple-drug therapy. 
To date, the association of the M235T variant with es- 
sential hypertension has been reported in two different 
studies (Jeunemaitre et al. 1992, 1993). In a study of 166 
hypertensive subjects from Paris, France and 264 hyper- 
tensive subjects from Salt Lake City, Utah, Jeunemaitre et 
al. (1992) showed an elevated M235T allele frequency as 
compared to normotensive controls. Hypertensive sub- 
jects in that study belonged to sibships with a family his- 
tory of hypertension ascertained either from a referral hy- 
pertension clinic (Paris sample) or from a self-reported 
health survey in the Utah population (Salt Lake City sam- 
ple; Jeunemaitre et al. 1992; Williams et al. 1988). Asso- 
ciation of the M235T variant allele of angiotensinogen 
with essential hypertension was also found in a second 
study of 119 hypertensives from Paris, France selected 
through a referral hypertension clinic and having a posi- 
tive family history of hypertension (Jeunemaitre et al. 
1993). Unlike these previous samples, our sample of hy- 
pertensive subjects was selected irrespective of family 
history of hypertension and not through a referral clinic. 
Absence of a strong genetic predisposition to hyperten- 
sion, as implied by the absence of a familial history, may 
in part be responsible for the lack of association between 
the M235T polymorphism and hypertension observed in 
our sample. However, recent data reporting no association 
between the M235T variant and hypertension in a sample 
of 92 hypertensive subjects from Sydney, Australia, hav- 
ing both parents with hypertension (Bennett et al. 1993) 
and in a sample of hypertensive index cases from 63 mul- 
tiplex pedigrees from England (Caulfield et al. 1994) in- 
dicate that absence of a family history of hypertension in 
our sample may not be sufficient to explain the discrep- 
ancy between the results reported here and those pub- 
lished in earlier reports (Jeunemaitre et al. 1992, 1993). 
Jeunemaitre et al. (1992) had previously observed a 
stronger association of the M235T variant and severe hy- 
pertension defined by the requirement of two or more 
anti-hypertensive drugs or a diastolic blood pressure over 
100 mm Hg. In addition, significant linkage of the an- 
giotensinogen gene and severe hypertension, as defined 
above, was obtained in both the Paris and Salt Lake City 
samples. Bennett et al. (1993) reported no association of 
the M235T variant of angiotensinogen with hypertension 
in 92 severely hypertensive subjects, as defined by greatly 
elevated diastolic and systolic blood pressures (DBP = 
112 + 18 mm Hg; SBP = 172 + 23 mm Hg). In this study, 
we found no association between genetic variation at the 
M235T locus of angiotensinogen and severe hyperten- 
sion, as defined by the requirement for two or more anti- 
hypertensive medications. 
Taken together, data from this and other studies sug- 
gest that the contribution of the angiotensinogen M235T 
polymorphism to essential hypertension in the general 
population may be less than originally suggested. Al- 
though, the effect of variation is this gene may be small in 
the general population, it may be greater in particular sub- 
sets of individuals. Therefore, the role of ascertainment 
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must  be carefully considered if a clear picture of the in- 
fluence of the M235T polymorphism is to be obtained. 
Because subjects selected through specialized clinics may 
have come to clinical attention because of occurrence of 
coronary heart disease, it is possible that the M235T allele 
may be associated with the cardiovascular complicat ions 
of hypertension,  rather than with elevated blood pressure 
itself. Interestingly, a polymorphism in the gene encoding 
another component  of the RAS angiotensin-conver t ing 
enzyme (ACE), has been associated with increased risk 
for myocardial  infarction (Cambien et al. 1992). 
The possibility must also be considered that the M235T 
polymorphism in the angiotensinogen gene does not lead to 
changes in function or regulation of the angiotensinogen 
protein. Data from Caulfield et al. (1994), confirming the 
linkage between a marker in the angiotensinogen gene and 
essential hypertension but not the association of the 
M235T polymorphism with essential hypertension, provide 
some support for this hypothesis. If the M235T polymor- 
phism is not functional, its association with essential hy- 
pertension is likely due to the effects of allelic variation at 
an unknown functional site within or near the an- 
giotensinogen gene and linkage disequilibrium between 
this unknown functional site and the M235T polymor- 
phism. If one considers the possibility that the linkage dis- 
equilibrium between the two loci may be different among 
populations, then the hypothesis of the M235T polymor- 
phism being a marker in linkage disequilibrium with a 
nearby functional site is compatible with the inconsistency 
in the results of previous association studies. Identification 
of functional sites following detection of significant link- 
age or association in studies of other complex traits has 
proven to be a formidable task. Several research strategies 
to identify these functional changes, such as cladistic 
analysis and DNA sequencing (Templeton et al. 1987; 
Deeb et al. 1992), have been proposed but have not yet 
yielded a comprehensive solution to this difficult problem. 
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